We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Sectra Extends Medical Diagnostics Business to Include Genomics IT

By LabMedica International staff writers
Posted on 02 Sep 2022
Print article
Image: Sectra\'s enterprise diagnostic IT platform will be extended to efficiently handle genomics information (Photo courtesy of Sectra)
Image: Sectra\'s enterprise diagnostic IT platform will be extended to efficiently handle genomics information (Photo courtesy of Sectra)

Analysis of genetic information, genomics, is used in healthcare today to better understand and diagnose patients and to predict how an individual patient may react to different treatments. Individualized care based on genetic information is often referred to as precision medicine and is a rapidly growing field. To leverage the possibilities of precision medicine and to cope with a dramatic increase in the volume of patient data, tomorrow's IT solutions for diagnostics need to provide healthcare providers with information across multiple specialties, including genomics, along with support for integrated diagnostic workflows.

Sectra (Linköping, Sweden), an international medical imaging IT and cybersecurity company, and the University of Pennsylvania Health System (Philadelphia, PA, USA), have initiated a collaboration to facilitate the development of an effective IT solution. Sectra is initiating a new business unit to drive innovation and product development within the area of genomics. In the future, Sectra's enterprise diagnostic IT platform will be extended to efficiently handle genomics information - a further step in Sectra's drive towards integrated diagnostics. This multidisciplinary approach is particularly important in cancer care.

The new business unit is part of Sectra's operating area Business Innovation. The IT solution for genomic information will be part of Sectra's enterprise imaging solution, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise.

"Genetic information is becoming increasingly important in diagnostics and precision medicine, especially within cancer care. Investing in genomics fits perfectly with our long-term ambition to be the leader in diagnostics information technology and has the potential to significantly impact patient care," says Torbjörn Kronander, President and CEO of Sectra.

New
Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
New
Silver Supplier
SARS-CoV-2, Influenza A/B Test
REALQUALITY ABFlu-Cov-2
New
Hemoglobin A1c Control
HbA1c (Auto)
New
Infliximab Immunoassay
RIDASCREEN IFX Monitoring

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.